Stock listing
NASDAQ:BMGL Basel Medical Group Ltd Stock
Home listing (NASDAQ) of Basel Medical Group Ltd
Follow Basel Medical Group Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:BMGL
$0.383 USD +0.025 (+7.0%)
Close on Nov 20, 2026
- Day range
- $0.290 – $0.383 USDNov 20, 2026
- Volume
- 1.05M sharesNov 20, 2026
- Market cap
- $2.91M USDAt the close on Nov 20, 2026 · price × 7.58M shares outstanding
- 52-week range
- $0.248 – $15.120 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.60M USDMedian day 160,600 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BMGL · Home | $0.383 USD | +0.025 (+7.0%) | 1,048,890 | $0.306 | $0.383 | $0.290 | $0.358 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BMGL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.383 | +0.025 | +7.0% | $0.306 | $0.383 | $0.290 | 1,048,890 | |
| $0.358 | +0.034 | +10.4% | $0.342 | $0.394 | $0.324 | 3,902,943 | |
| $0.325 | +0.022 | +7.3% | $0.370 | $0.380 | $0.248 | 61,646,809 | |
| $0.302 | -0.168 | -35.7% | $0.440 | $0.460 | $0.275 | 1,272,340 | |
| $0.470 | -0.100 | -17.5% | $0.530 | $0.550 | $0.450 | 620,622 | |
| $0.570 | -0.114 | -16.7% | $0.600 | $0.649 | $0.513 | 1,602,033 | |
| $0.684 | -1.246 | -64.6% | $1.060 | $1.060 | $0.600 | 4,815,800 | |
| $1.930 | -3.470 | -64.3% | $5.380 | $5.490 | $1.530 | 15,609,900 | |
| $5.400 | +0.110 | +2.1% | $5.305 | $5.460 | $4.750 | 1,387,700 | |
| $5.290 | +0.100 | +1.9% | $5.190 | $5.330 | $5.120 | 1,684,900 | |
| $5.190 | 0.000 | 0.0% | $5.200 | $5.300 | $5.125 | 2,400,500 | |
| $5.190 | -0.020 | -0.4% | $5.260 | $5.490 | $5.150 | 1,437,700 | |
| $5.210 | +0.100 | +2.0% | $5.180 | $5.270 | $5.130 | 172,500 | |
| $5.110 | +0.070 | +1.4% | $5.020 | $5.200 | $4.950 | 1,881,400 | |
| $5.040 | +0.290 | +6.1% | $4.760 | $5.090 | $4.750 | 1,781,600 | |
| $4.750 | +0.150 | +3.3% | $4.590 | $4.940 | $4.550 | 1,319,400 | |
| $4.600 | -0.030 | -0.6% | $4.590 | $4.700 | $4.510 | 2,013,100 | |
| $4.630 | +0.080 | +1.8% | $4.560 | $4.630 | $4.500 | 1,065,700 | |
| $4.550 | +0.110 | +2.5% | $4.440 | $4.550 | $4.410 | 1,601,800 | |
| $4.440 | -0.010 | -0.2% | $4.430 | $4.500 | $4.380 | 1,642,000 | |
| $4.450 | +0.020 | +0.5% | $4.430 | $4.710 | $4.430 | 993,700 | |
| $4.430 | +0.250 | +6.0% | $4.200 | $4.450 | $4.070 | 1,203,000 | |
| $4.180 | +0.130 | +3.2% | $4.080 | $4.290 | $4.030 | 1,345,800 | |
| $4.050 | +0.100 | +2.5% | $3.930 | $4.110 | $3.770 | 1,743,800 | |
| $3.950 | +0.040 | +1.0% | $3.970 | $3.970 | $3.800 | 1,448,500 | |
| $3.910 | +0.060 | +1.6% | $3.940 | $3.940 | $3.780 | 1,436,800 | |
| $3.850 | 0.000 | 0.0% | $3.880 | $4.140 | $3.750 | 1,601,100 | |
| $3.850 | +0.140 | +3.8% | $3.870 | $4.170 | $3.710 | 1,138,000 | |
| $3.710 | -0.040 | -1.1% | $3.570 | $4.300 | $3.570 | 471,500 | |
| $3.750 | +0.150 | +4.2% | $3.500 | $3.880 | $3.430 | 104,000 | |
| $3.600 | +0.320 | +9.8% | $3.200 | $3.740 | $2.560 | 126,900 | |
| $3.280 | -0.050 | -1.5% | $3.200 | $3.300 | $3.180 | 12,600 | |
| $3.330 | +0.160 | +5.0% | $3.250 | $3.330 | $3.200 | 9,600 | |
| $3.170 | -0.110 | -3.4% | $3.225 | $3.550 | $3.170 | 13,400 | |
| $3.280 | +0.260 | +8.6% | $3.050 | $3.350 | $2.950 | 25,200 | |
| $3.020 | -0.100 | -3.2% | $3.120 | $3.250 | $3.020 | 10,400 | |
| $3.120 | +0.020 | +0.6% | $3.310 | $3.310 | $3.030 | 7,000 | |
| $3.100 | -0.370 | -10.7% | $3.430 | $3.440 | $3.040 | 130,500 | |
| $3.470 | -0.230 | -6.2% | $3.700 | $3.700 | $3.450 | 12,700 | |
| $3.700 | -0.100 | -2.6% | $3.800 | $3.844 | $3.680 | 4,700 | |
| $3.800 | -0.290 | -7.1% | $4.089 | $4.090 | $3.700 | 61,500 | |
| $4.090 | -0.100 | -2.4% | $4.080 | $4.240 | $3.880 | 40,900 | |
| $4.190 | -0.400 | -8.7% | $4.500 | $4.600 | $3.890 | 43,200 | |
| $4.590 | -0.020 | -0.4% | $4.500 | $4.840 | $4.370 | 22,700 | |
| $4.610 | +0.300 | +7.0% | $4.700 | $5.200 | $4.610 | 35,600 | |
| $4.310 | +0.210 | +5.1% | $4.300 | $5.503 | $4.300 | 118,100 | |
| $4.100 | -1.240 | -23.2% | $4.500 | $5.128 | $3.900 | 160,600 | |
| $5.340 | -1.800 | -25.2% | $6.000 | $6.590 | $5.221 | 389,300 | |
| $7.140 | +2.560 | +55.9% | $8.060 | $9.220 | $6.830 | 31,904,000 | |
| $4.580 | 0.000 | 0.0% | $4.580 | $4.580 | $4.580 | 0 | |
| $4.580 | -0.200 | -4.2% | $4.580 | $4.690 | $4.580 | 2,800 | |
| $4.780 | 0.000 | 0.0% | $4.780 | $4.780 | $4.780 | 0 | |
| $4.780 | 0.000 | 0.0% | $4.580 | $5.000 | $4.580 | 1,200 | |
| $4.780 | 0.000 | 0.0% | $4.780 | $4.780 | $4.780 | 0 | |
| $4.780 | -0.160 | -3.2% | $4.950 | $4.950 | $4.780 | 600 | |
| $4.940 | -0.140 | -2.8% | $5.080 | $5.080 | $4.510 | 3,000 | |
| $5.080 | -0.480 | -8.6% | $5.120 | $5.160 | $5.080 | 1,200 | |
| $5.560 | +0.320 | +6.1% | $5.090 | $5.560 | $5.080 | 3,700 | |
| $5.240 | -0.210 | -3.9% | $5.250 | $5.340 | $5.170 | 10,900 | |
| $5.450 | -0.485 | -8.2% | $5.395 | $5.600 | $4.800 | 38,800 | |
| $5.935 | +1.135 | +23.6% | $4.540 | $6.000 | $4.490 | 222,200 | |
| $4.800 | 0.000 | 0.0% | $4.800 | $4.800 | $4.800 | 0 | |
| $4.800 | -0.500 | -9.4% | $4.800 | $4.990 | $4.800 | 1,200 | |
| $5.300 | +0.400 | +8.2% | $4.980 | $5.300 | $4.550 | 11,600 | |
| $4.900 | -0.030 | -0.6% | $4.492 | $4.900 | $4.492 | 1,100 |
Splits
1 split · NASDAQ:BMGL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation |
- Ticker
- NASDAQ:BMGL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Health care services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 9, 2026
Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering
Latest news
Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering
Oct 9, 2026
Closed $3.71 (-1.1%) on Oct 12, 2026
Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering
Oct 8, 2026
Closed $3.60 (+9.8%) on Oct 8, 2026
BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement
Jul 10, 2026
Closed $6.61 (-0.2%) on Jul 10, 2026
BMGL to Effect Reverse Share Split on June 22, 2026
Jun 10, 2026
Closed $7.04 (-8.0%) on Jun 10, 2026
Compliance With Nasdaq Periodic Filing Requirement
Mar 24, 2026
Closed $7.68 (-7.2%) on Mar 24, 2026
Amendment to Annual Report by Foreign Issuer (Form 20-F/A)
Mar 13, 2026
Closed $7.43 (+3.7%) on Mar 13, 2026
Receipt of Delinquency Notification from Nasdaq
Jan 23, 2026
Closed $9.26 (-3.5%) on Jan 26, 2026
Basel Medical Group Ltd on 6ix
- Sector
- Health care
- Industry
- Health care services
- News releases
- 7 in the last 12 months · 18 in all · newest Oct 9, 2026 · oldest 2025
Where Basel Medical Group Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BMGL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BMGL | BOATS | United States | USD |
Valuation
EV/sales 0.6× against a median of 3.1×: 3rd lowest of 8 Health care services companies shown. Statements: Year to Jun 30, 2026 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $9.95M USD
- P/E
- Loss
- EV/sales
- 0.6×
- EV/EBITDA
- 1.1×
- Price/book
- 0.7×
- Gross margin
- 38.8%
- Operating margin
- 38.7%
- Net margin
- −3.5%
- Debt to equity
- 1.9×
- Beta vs S&P 500
- 0.58
Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Basel Medical Group Ltd · NASDAQ:BMGL | US$2.91M | US$9.95M | n/a | 0.6× | 1.1× | 0.7× | −3.5% | 1.9× | 0.58 |
| Amesite Inc. · NASDAQ:AMST | US$3.34M | US$1.64M | n/a | 4.8× | n/a | 1.7× | −947.4% | 0.0× | 1.13 |
| Regional Health Properties, Inc. · OTC:RHEP | US$3.30M | US$43.79M | 17.6× | 0.5× | 8.7× | n/a | 0.2% | n/a | 0.34 |
| Seegnal Inc. · TSXV:SEGN | US$3.26M | US$4.27M | n/a | 3.1× | n/a | n/a | −468.5% | n/a | 0.26 |
| PanGenomic Health, Inc. Class A · CSE:NARA | US$3.23M | US$3.22M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| Polomar Health Services, Inc. · OTC:PMHS | US$2.84M | US$2.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.25 |
| Mangoceuticals, Inc. · NASDAQ:MGRX | US$2.75M | US$2.73M | n/a | 9.1× | n/a | 0.3× | n/a | 0.1× | 0.60 |
| UniDoc Health Corp. · CSE:UDOC | US$2.71M | US$2.66M | n/a | 4.0× | n/a | n/a | −327.1% | n/a | -0.61 |
| Modern Mobility Aids, Inc. · OTC:MDRM | US$2.68M | US$2.71M | n/a | n/a | n/a | n/a | n/a | n/a | -0.74 |
| Healthcare Triangle, Inc. · NASDAQ:HCTI | US$2.63M | US$17.54M | n/a | 0.6× | n/a | 0.1× | −56.4% | 0.3× | 2.08 |
| Monsenso A/S · OMXCOP:MONSO | US$2.57M | US$2.69M | n/a | 2.1× | n/a | 2.6× | −81.0% | 0.1× | n/a |
| Median of the others | US$2.79M | US$2.72M | 17.6× | 3.1× | 8.7× | 1.0× | −204.1% | 0.1× | 0.26 |
Team and board
Officers
| Officer | Role |
|---|---|
| Darren Chhoa | Group Chief Executive Officer (GCEO) |
| Neo Chun How Alton | Group Chief Financial Officer (GCFO) |
| Darren Tan | Group Chief Commercial Officer (GCCO) |
Board
| Director | Role |
|---|---|
| Cao Juan | |
| Darren Chhoa | Group Chief Executive Officer (GCEO) |
| Darren Tan | Group Chief Commercial Officer (GCCO) |
| Federick Hong | |
| Kwek Yoon Soong | |
| Neo Chun How Alton | Group Chief Financial Officer (GCFO) |
| Paul Freudenthaler | |
| Tony Chen | |
| Yang Xinwen |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2026 | Nov 18, 2025 | +2.7% |
| Q3 2025 | Jun 18, 2025 | −10.3% |
| Quarter to Sep 30, 2024 | Nov 4, 2024 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of units (ordinary share or pre-funded warrant plus common warrant) Closed: US$7.98M raised · US$1.33 a unit · one Common Warrant to purchase one Ordinary Share, exercisable immediately at 110% of… · Cathay Securities, Inc. Dealers: Cathay Securities, Inc. (lead) Use of proceeds: General working capital, mergers and acquisitions and other general corporate purposes | Oct 9, 2026 |
| Public offering of ordinary shares Closed: US$10.14M raised · US$4 a share · Cathay Securities, Inc. +1 Dealers: Cathay Securities, Inc. (lead), Revere Securities LLC Use of proceeds: Potential mergers and acquisitions, business expansion (clinic space, auxiliary services, staff, technology, marketing), and working capital | Mar 19, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Feb 24, 2025.
- Price
- US$4.00 a share
- Shares offered
- 2,205,000 ordinary shares
- Offering size
- US$8.8 million
- Underwriters' option
- Up to 330,750 more shares
- Underwriters
- CATHAY SECURITIES, INC., REVERE SECURITIES LLC · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 9, 2024 |
| Filed publicly | Sep 13, 2024 |
| Amended 4 times | Newest Feb 13, 2025 |
| Shares registered with an exchange | Feb 14, 2025 |
| Declared effective by the SEC | Feb 18, 2025 |
| Final prospectus, with the price | Feb 25, 2025 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 25, 2025 |
| 424B4 · Prospectus | Feb 25, 2025 |
| CERT · Exchange's certificate of listing | Feb 21, 2025 |
| EFFECT · Notice that a registration is effective | Feb 18, 2025 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 14, 2025 |
| CORRESP · Letter to the SEC | Feb 14, 2025 |
| CORRESP · Letter to the SEC | Feb 14, 2025 |
| F-1/A · Registration statement, amended | Feb 13, 2025 |
| FWP · Free writing prospectus | Dec 13, 2024 |
| CORRESP · Letter to the SEC | Dec 3, 2024 |
All 32 filings
Open IPO · From the cover of the final prospectus (424B4) filed Feb 25, 2025
Financials
Annual, in SGD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 21.5M | 11.3M | 10.1M | 9.70M | 10.7M |
| Cost of revenue | 13.2M | 2.53M | 2.25M | 2.34M | 2.18M |
| Gross profit | 8.34M | 8.79M | 7.80M | 7.36M | 8.48M |
| Selling, general and administrative | 9.24M | 6.54M | 3.64M | 3.27M | 4.04M |
| Operating income | 8.33M | -2.18M | 2.20M | 2.00M | 2.47M |
| Depreciation and amortization | 3.90M | 107.7K | 30.1K | 557.1K | 575.9K |
| EBITDA | 12.2M | -2.08M | 2.23M | 2.56M | 3.05M |
| Interest expense | 460.0K | 203.9K | 176.2K | 238.6K | 320.9K |
| Income before tax | -1.25M | -11.1M | 2.40M | 2.13M | 2.39M |
| Income tax | 179.6K | -417.4K | 331.8K | 348.3K | 408.5K |
| Net income | -748.0K | -10.6M | 2.07M | 1.78M | 1.98M |
| Earnings per share, basic | -0.47 | -0.64 | 0.13 | 1.32 | 1.46 |
| Earnings per share, diluted | -0.57 | 0.13 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash and equivalents | 529.9K | 3.04M | 1.95M | 1.22M | 1.56M |
| Receivables | 10.3M | 9.49M | 2.01M | 13.3M | 13.9M |
| Inventory | 230.9K | 489.1K | 72.0K | 94.6K | 69.8K |
| Current assets | 12.1M | 13.3M | 16.2M | 14.8M | 15.7M |
| Property, plant and equipment | 388.7K | 34.5K | |||
| Goodwill | 10.3M | ||||
| Total assets | 17.8M | 18.7M | 16.3M | 15.4M | 16.8M |
| Accounts payable | 3.55M | 6.57M | 2.58M | 1.46M | 1.08M |
| Current liabilities | 9.86M | 10.2M | 7.16M | 6.47M | 7.19M |
| Long-term debt | 2.96M | 1.58M | 3.40M | 5.31M | |
| Total debt | 9.62M | 10.2M | 8.58M | 7.21M | 10.2M |
| Total liabilities | 13.3M | 13.2M | 8.75M | 9.89M | 13.1M |
| Shareholders' equity | 5.06M | 5.44M | 7.56M | 5.49M | 3.71M |
| Shares outstanding | 1.58M | 1.56M | 1.35M | 1.35M | 1.35M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cash from operations | -635.2K | -4.04M | 2.51M | 2.60M | 2.79M |
| Capital spending | -248.2K | -556.9K | -7.92K | -6.16K | -88.5K |
| Free cash flow | -883.4K | -4.60M | 2.50M | 2.59M | 2.70M |
| Cash from investing | -104.2K | -10.9M | -7.92K | -6.16K | -88.5K |
| Cash from financing | -1.78M | 16.5M | -1.77M | -2.94M | -12.9M |
| Change in cash | -2.51M | 1.56M | 733.6K | -346.2K | -10.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 20-F · Annual report | Oct 30, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 21, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2026 | Current report | SEC |
| 424B4 · Prospectus | Oct 8, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Oct 1, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 30, 2026 | Other filings | SEC |
| F-1/A · Registration statement, amended | Sep 23, 2026 | Offer document | SEC |
| F-1 · Registration statement | Sep 17, 2026 | Offer document | SEC |
All 84 filings
Cap table
Built by 6ix from Basel Medical Group Ltd’s releases · as of Oct 9, 2026
- Common shares
- 7,582,111
- Fully diluted
- 13,582,111
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 7,582,111 | Oct 9, 2026 |
| Warrants | 6,000,000 | Oct 9, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · expire about Oct 2031 |
Share count over time
| Count | Shares |
|---|---|
| Oct 9, 2026 | 7,582,111 |
| Jun 10, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul Freudenthaler Other companies: Freight Technologies, Inc. (Secretary · Since at least Feb 21, 2025) | Director · Since at least Feb 18, 2025 |
| Alton Chun How Neo | Interim CFO · Since at least Jun 5, 2026 |
| Boon Chye Tan | Chief Commercial Officer, Director · Since at least Mar 18, 2026 |
| Cao Juan | Director · Since at least Nov 5, 2026 |
| Darren Chhoa | Group Chief Executive Officer (GCEO) · Since at least May 29, 2025 |
| Darren Tan | Group Chief Commercial Officer (GCCO) · Since at least Nov 5, 2026 |
| Federick Hong | Director · Since at least Nov 5, 2026 |
| Jianing JN Lu | Chief Financial Officer · Since at least Mar 18, 2026 |
| Keng Leong Fung | Director · Since at least Mar 18, 2026 |
| Kwek Yoon Soong | Director · Since at least Mar 18, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Neo Chun How Alton | Group Chief Financial Officer (GCFO) · Since at least Nov 5, 2026 |
| Tony Chen | Director · Since at least Nov 4, 2026 |
| Tony Chen | Director · Since at least Mar 18, 2026 |
| Yang Xinwen | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Basel Medical Group Ltd.